Eric Jordie, M.S.

Vice President of TSP, Quantitative Sciences

Aside from his first seven years modeling planetary and biological systems at NASA, Eric’s twenty-year career has focused on the strategic application of advanced analytics, modeling, and simulation techniques to interpret and integrate biopharmaceutical data and to quantitatively inform pre-clinical through late phase clinical drug development decision making. In particular, Eric has extensive industrial experience developing and applying a broad continuum of translational, pharmacometric, and systems pharmacology techniques and strategies across diverse therapeutic areas. Eric is especially passionate about collaborations focused on developing and implementing quantitative frameworks used to advance the development of immunotherapeutics.

Recent publications by this scientist

A physiologically-based pharmacokinetic modeling approach to support candidate and first in human dose selection for bamlanivimab

September 3, 2021

Tim Knab, Ahmed Elmokadem, Emmanuel Chigutsa, Eric Jordie, Matthew Riggs, Patricia Brown-Augsburger, Christopher Wiethoff, Ajay Nirula, Jenny Y Chien, Lisa O’Brien.  Poster presented at Population Approach Group Europe Annual Meeting; 2-3 and 6-7 September 2021.  Poster I-64.

Download PDF

Dosing regimen optimisation for oseltamivir in immunocompromised paediatric patients with influenza: Extrapolation of efficacy

August 27, 2021

Jordie EB, Gibiansky L, Knab T, Lemenuel-Diot A, Ravva P, Zwanziger E, Jolivet S, Bhardwaj R, Hernández-Sánchez J, Nasmyth-Miller C, Sturm S. Br J Clin Pharmacol. 2021;1-13. doi:10.1111/bcp.15059

View More

Impact of Obesity on Brexpiprazole Pharmacokinetics: Proposal for Improved Initiation of Treatment

August 2, 2021

Bruno CD, Elmokadem A, Housand C, Jordie EB, Chow CR, Laughren T, Greenblatt DJ. Journal of Clinical Pharmacology.  2021;62(1):55-65. doi:10.1002/jcph.1947

View More